Articles

The roles of GTPase-activating proteins in regulated cell death and tumor immunity

GTPase-activating protein (GAP) is a negative regulator of GTPase protein that is thought to promote the conversion of the active GTPase-GTP form to the GTPase-GDP form. Based on its ability to regulate GTPase...

Authors: Hua He, Jingjing Huang, Sufang Wu, Shiyao Jiang, Lu Liang, Yueying Liu, Wenbing Liu, Li Xie, Yongguang Tao, Yiqun Jiang and Li Cong

Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation

Lineage plasticity, the ability to transdifferentiate among distinct phenotypic identities, facilitates therapeutic resistance in cancer. In lung adenocarcinomas (LUADs), this phenomenon includes small cell an...

Authors: Alvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yingqian A. Zhan, Maysun M. Hasan, Shweta S. Chavan, Fanli Meng, Fathema Uddin, Viola Allaj, Parvathy Manoj, Nisargbhai S. Shah, Joseph M. Chan, Metamia Ciampricotti, Andrew Chow, Michael Offin, Jordana Ray-Kirton, Jacklynn D. Egger…

Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers

Altered metabolic patterns in tumor cells not only meet their own growth requirements but also shape an immunosuppressive microenvironment through multiple mechanisms. Noncoding RNAs constitute approximately 6...

Authors: Yiyin Zhang, Qijiang Mao, Qiming Xia, Jiaxi Cheng, Zhengze Huang, Yirun Li, Peng Chen, Jing Yang, Xiaoxiao Fan, Yuelong Liang and Hui Lin

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management ...

Authors: Livio Pagano, Jon Salmanton-García, Francesco Marchesi, Alessandro Busca, Paolo Corradini, Martin Hoenigl, Nikolai Klimko, Philipp Koehler, Antonio Pagliuca, Francesco Passamonti, Luisa Verga, Benjamin Víšek, Osman Ilhan, Gianpaolo Nadali, Barbora Weinbergerová, Raúl Córdoba-Mascuñano…

Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials

Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with a high initial response rate followed almost invariably by relapse. Here we report the pooled data from 2 studies, BGB-3111-AU-003 and BGB-3111-206, ...

Authors: Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Daobin Zhou, Constantine S. Tam, David Simpson, Michael Wang…

Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls

Patients with multiple myeloma are at high risk of severe forms of COVID-19. Despite data showing diminished response to vaccine, the era of highly efficient mRNA vaccine might be a gamechanger. We sought to e...

Authors: Samuel Bitoun, Julien Henry, Christelle Vauloup-Fellous, Nicolas Dib, Rakiba Belkhir, Lina Mouna, Candie Joly, Delphine Desjardins, Marie Bitu, Roger Le Grand, Raphaèle Seror, Anne-Marie Roque Afonso and Xavier Mariette

Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma

Although adjuvant transcatheter arterial chemoembolization (TACE) for resected hepatocellular carcinoma (HCC) may improve survival for some patients, identifying which patients can benefit remains challenging....

Authors: Lei Liang, Chao Li, Ming-Da Wang, Hong Wang, Ya-Hao Zhou, Yong-Yi Zeng, Wan-Guang Zhang, Ting-Hao Chen, Nan-Ya Wang, Jie Li, Yao-Ming Zhang, Yu Wang, Wei-Min Gu, Hao Xing, Yong-Kang Diao, Wan Yee Lau…

Personalized analysis of minimal residual cancer cells in peritoneal lavage fluid predicts peritoneal dissemination of gastric cancer

Peritoneal dissemination (PD) is a major type of gastric cancer (GC) recurrence and leads to rapid death. Current approaches cannot precisely determine which patients are at high risk of PD to provide early in...

Authors: Dongbing Zhao, Pinli Yue, Tongbo Wang, Pei Wang, Qianqian Song, Jingjing Wang and Yuchen Jiao

COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently constitutes the leading and overwhelming health issue worldwide. In comparison with adults, ...

Authors: Jadwiga Węcławek-Tompol, Zuzanna Zakrzewska, Olga Gryniewicz-Kwiatkowska, Filip Pierlejewski, Ewa Bień, Agnieszka Zaucha-Prażmo, Olga Zając-Spychała, Anna Szmydki-Baran, Agnieszka Mizia-Malarz, Wioletta Bal, Małgorzata Sawicka-Żukowska, Agnieszka Kruk, Anna Raciborska, Agnieszka Książek, Tomasz Szczepański, Jarosław Peregud-Pogorzelski…

CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity

CAR T cell therapy has shown dramatic clinical success in relapsed or refractory B-ALL and other hematological malignancies. However, the loss of specific antigens, cell fratricide, T cell aplasia, and normal ...

Authors: Jiangzhou Shi, Zijian Zhang, Hong Cen, Han Wu, Shangkun Zhang, Jiaxing Liu, Yingqi Leng, Anqi Ren, Xiyu Liu, Zhijie Zhang, Xiqin Tong, Jinjue Liang, Zhe Li, Fuling Zhou, Liang Huang, You Qin…

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma

BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary resistance and relapse exist with single-target i...

Authors: Heng Mei, Chenggong Li, Huiwen Jiang, Xinying Zhao, Zhiping Huang, Dan Jin, Tao Guo, Haiming Kou, Lin Liu, Lu Tang, Ping Yin, Zhihui Wang, Lisha Ai, Sha Ke, Yimeng Xia, Jun Deng…

Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes

In this era of precision medicine, with the help of biomarkers, immunotherapy has significantly improved prognosis of many patients with malignant tumor. Deficient mismatch repair (dMMR)/microsatellite instabi...

Authors: Wantao Wu, Yihan Liu, Shan Zeng, Ying Han and Hong Shen

Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report

New targeted antibody–drug conjugates (ADCs) against multiple myeloma are known to induce adverse effects that may lead to treatment discontinuation. Preclinical studies reported early severe ocular damage rel...

Authors: Kevin Marquant, Anne Quinquenel, Carl Arndt and Alexandre Denoyer

Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine

Authors: Zhaojin Yu, Wensi Liu, Ying He, Mingli Sun, Jiankun Yu, Xue Jiao, Qiang Han, Haichao Tang, Bing Zhang, Yunkai Xian, Jing Qi, Jing Gong, Wang Xin, Gang Shi, Fengping Shan, Rui Zhang…

Targeting mutant p53 for cancer therapy: direct and indirect strategies

TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 protein oncogenic properties. ...

Authors: Jiahao Hu, Jiasheng Cao, Win Topatana, Sarun Juengpanich, Shijie Li, Bin Zhang, Jiliang Shen, Liuxin Cai, Xiujun Cai and Mingyu Chen

Combination strategies to maximize the benefits of cancer immunotherapy

Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially in patients whose disease was otherwise considered incurable. However, ...

Authors: Shaoming Zhu, Tian Zhang, Lei Zheng, Hongtao Liu, Wenru Song, Delong Liu, Zihai Li and Chong-xian Pan

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells

Acute myeloid leukaemia (AML) stem cells (LSCs) cause disease relapse. The CD47 “don’t eat me signal” is upregulated on LSCs and contributes to immune evasion by inhibiting phagocytosis through interacting wit...

Authors: Siret Tahk, Binje Vick, Björn Hiller, Saskia Schmitt, Anetta Marcinek, Enrico D. Perini, Alexandra Leutbecher, Christian Augsberger, Anna Reischer, Benjamin Tast, Andreas Humpe, Irmela Jeremias, Marion Subklewe, Nadja C. Fenn and Karl-Peter Hopfner

Deep learning for differential diagnosis of malignant hepatic tumors based on multi-phase contrast-enhanced CT and clinical data

Liver cancer remains the leading cause of cancer death globally, and the treatment strategies are distinct for each type of malignant hepatic tumors. However, the differential diagnosis before surgery is chall...

Authors: Ruitian Gao, Shuai Zhao, Kedeerya Aishanjiang, Hao Cai, Ting Wei, Yichi Zhang, Zhikun Liu, Jie Zhou, Bing Han, Jian Wang, Han Ding, Yingbin Liu, Xiao Xu, Zhangsheng Yu and Jinyang Gu

Kynurenine derivative 3-HAA is an agonist ligand for transcription factor YY1

The 3-hydroxyanthranilic acid (3-HAA), a derivative of kynurenine, was reported to suppress tumor growth. However, the function of 3-HAA largely remains unclear. Here, we report that 3-hydroxyanthranilic acid ...

Authors: Zhaopeng Shi, Guifang Gan, Xiang Xu, Jieying Zhang, Yuan Yuan, Bo Bi, Xianfu Gao, Pengfei Xu, Wenbin Zeng, Jixi Li, Youqiong Ye, Aiwu Zhou, Naixia Zhang, Wen Liu, Shuhai Lin and Jun Mi

Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway

Chimeric antigen receptor T-cell (CAR-T) therapy has shown tremendous success in eradicating hematologic malignancies. However, this success has not yet been extrapolated to solid tumors due to the limited inf...

Authors: Feng Ji, Fan Zhang, Miaomiao Zhang, Kaili Long, Mingyue Xia, Fei Lu, Enjie Li, Jiannan Chen, Jun Li, Zhengliang Chen, Li Jing, Shaochang Jia, Rong Yang, Zhigang Hu and Zhigang Guo

Prognostic and predictive biomarker developments in multiple myeloma

New approaches to stratify multiple myeloma patients based on prognosis and therapeutic decision-making, or prediction, are needed since patients are currently managed in a similar manner regardless of individ...

Authors: Craig T. Wallington-Beddoe and Rachel L. Mynott

Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy

Authors: Chunmeng Wang, Fengxia Shi, Yang Liu, Yajing Zhang, Liang Dong, Xiang Li, Chuan Tong, Yao Wang, Liping Su, Jing Nie and Weidong Han

Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia

CD19 chimeric antigen receptor (CAR)-T cells have been used to treat patients with refractory chronic lymphocytic leukemia (CLL). However, approximately 50% of patients do not respond to this therapy. To impro...

Authors: Guoling Wang, Xiaolei Sun, Shiyu Zuo, Chuo Li, Qing Niu, Yonghui Xia, Yuan Meng, Min Liu, Zihao Fang, Xi Yang, Yanyu Jiang, Sheng Wang, Haidong Cui, Huifang Huang, Erlie Jiang, Dongming Zhou…

KAI1(CD82) is a key molecule to control angiogenesis and switch angiogenic milieu to quiescent state

Little is known about endogenous inhibitors of angiogenic growth factors. In this study, we identified a novel endogenous anti-angiogenic factor expressed in pericytes and clarified its underlying mechanism an...

Authors: Jin-Woo Lee, Jin Hur, Yoo-Wook Kwon, Cheong-Whan Chae, Jae-Il Choi, Injoo Hwang, Ji-Yeon Yun, Jin-A Kang, Young-Eun Choi, Young Hyun Kim, Sang Eun Lee, Cheol Lee, Dong Hyun Jo, Heeyoung Seok, Byong Seung Cho, Sung Hee Baek…

Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target

Immune checkpoint therapy has achieved significant efficacy by blocking inhibitory pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death protein 1/programmed cell death l...

Authors: Wenjing Qian, Mingfang Zhao, Ruoyu Wang and Heming Li

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers

Our previous work showed that the anti-TGF-β/PD-L1 bispecific antibody YM101 effectively overcame anti-PD-L1 resistance in immune-excluded tumor models. However, in immune-desert models, the efficacy of YM101 ...

Authors: Ming Yi, Mengke Niu, Jing Zhang, Shiyu Li, Shuangli Zhu, Yongxiang Yan, Ning Li, Pengfei Zhou, Qian Chu and Kongming Wu

The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update

The consensus recommendations in 2018 from The Chinese Society of Hematology (CSH) on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation (allo-HSCT) f...

Authors: Xiao-hui Zhang, Jing Chen, Ming-Zhe Han, He Huang, Er-lie Jiang, Ming Jiang, Yong-rong Lai, Dai-hong Liu, Qi-Fa Liu, Ting Liu, Han-yun Ren, Yong-Ping Song, Zi-min Sun, Xiao-wen Tang, Jian-min Wang, De-pei Wu…

Correction to: Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N⁶-methyladenosine of PARP1 mRNA and downregulating PTEN

Authors: Lei Yang, Yi Chen, Ning Liu, QianCheng Shi, Xiaodong Han, Weidong Gan and Dongmei Li

HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast

Malignant adenomyoepithelioma (AME) of the breast is an exceptionally rare form of breast cancer, with a significant metastatic potential. Chemotherapy has been used in the management of advanced AME patients,...

Authors: Ivan Bièche, Florence Coussy, Rania El-Botty, Sophie Vacher, Sophie Château-Joubert, Ahmed Dahmani, Elodie Montaudon, Cécile Reyes, David Gentien, Fabien Reyal, Francesco Ricci, André Nicolas, Caterina Marchio, Anne Vincent-Salomon, Marick Laé and Elisabetta Marangoni

Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response

Tumor microenvironment (TME) is a dynamic cellular milieu to promote tumor angiogenesis, growth, proliferation, and metastasis, while derailing the host anti-tumor response. TME impedes bispecific antibody (Bs...

Authors: Jeong A. Park, Linlin Wang and Nai-Kong V. Cheung

Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications

Pancreatic cancer has the worst prognosis among common tumors which is attributed to its aggressive phenotype, diagnosis at advanced, inoperable stages, and resistance to systemic therapy. Non-coding RNAs (ncR...

Authors: Moritz Reese and Sameer A. Dhayat

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma

In the absence of randomized studies directly comparing chimeric antigen receptor T cell therapies, this study used matching-adjusted indirect comparisons (MAIC) to evaluate the comparative efficacy and safety...

Authors: David G. Maloney, John Kuruvilla, Fei Fei Liu, Ana Kostic, Yeonhee Kim, Ashley Bonner, Yixie Zhang, Christopher P. Fox and Guillaume Cartron

Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells

The pathogenesis of chronic myeloid leukemia (CML) is the formation of the BCR/ABL protein, which is encoded by the bcr/abl fusion gene, possessing abnormal tyrosine kinase activity. Despite the wide applicati...

Authors: Guoyun Jiang, Zhenglan Huang, Ying Yuan, Kun Tao and Wenli Feng

Protein degradation technology: a strategic paradigm shift in drug discovery

Targeting pathogenic proteins with small-molecule inhibitors (SMIs) has become a widely used strategy for treating malignant tumors. However, most intracellular proteins have been proven to be undruggable due ...

Authors: Haobin Li, Jinyun Dong, Maohua Cai, Zhiyuan Xu, Xiang-Dong Cheng and Jiang-Jiang Qin

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia

Quantification of measurable residual disease (MRD) provides critical prognostic information in acute myeloid leukemia (AML). A variety of platforms exist for MRD detection, varying in their sensitivity and ap...

Authors: Marisa J. L. Aitken, Farhad Ravandi, Keyur P. Patel and Nicholas J. Short

Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer

Extracellular vesicles (EVs) are cell-derived membrane structures enclosing proteins, lipids, RNAs, metabolites, growth factors, and cytokines. EVs have emerged as essential intercellular communication regulat...

Authors: Zhijie Weng, Bowen Zhang, Chenzhou Wu, Fanyuan Yu, Bo Han, Bo Li and Longjiang Li

Correction to: MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

Authors: Seyed Esmaeil Ahmadi, Samira Rahimi, Bahman Zarandi, Rouzbeh Chegeni and Majid Safa

Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer

Hepatocellular carcinoma (HCC) is one of the most common malignancies globally. Despite aggressive and multimodal treatment regimens, the overall survival of HCC patients remains poor.

Authors: Hao Shen, Boqiang Liu, Junjie Xu, Bin Zhang, Yifan Wang, Liang Shi and Xiujun Cai

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal. In the pivotal QUAZAR AML-0...

Authors: Farhad Ravandi, Gail J. Roboz, Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Dominik Selleslag, Pau Montesinos, Hamid Sayar, Maurizio Musso, Angela Figuera-Alvarez, Hana Safah, William Tse, Sang Kyun Sohn, Devendra Hiwase, Timothy Chevassut, Francesca Pierdomenico…

The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma

Mantle cell lymphoma (MCL) is a rare, aggressive and incurable subtype of non-Hodgkin’s B-cell lymphoma. The principal barrier is frequent clinical relapse to multiple lines of therapies, including new FDA-app...

Authors: Vivian Changying Jiang, Yang Liu, Alexa Jordan, Joseph McIntosh, Yijing Li, Yuxuan Che, Katti A. Jessen, Brian J. Lannutti and Michael Wang

Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China

Clinical features and outcomes of FL patients in Chinese population are limited, thus promoting us to perform this analysis on a large cohort of 1845 patients with FL enrolled from nine medical centers nationw...

Authors: Jie Zha, Liyuan Fan, Shuhua Yi, Haifeng Yu, Zhong Zheng, Wei Xu, Manman Deng, Zhijuan Lin, Zhifeng Li, Lingyan Ping, Xiaohua He, Feili Chen, Ying Xie, Biyun Chen, Huilai Zhang, Li Wang…

Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies

YY-20394, an oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, was investigated in a first-in-human study of patients with relapsed or refractory B-cell malignancies. During dose escalation, 25 patie...

Authors: Bo Jiang, Junyuan Qi, Yuqin Song, Zengjun Li, Meifeng Tu, Lingyan Ping, Zongliang Liu, Hanying Bao, Zusheng Xu and Lugui Qiu

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer

METex14 skipping mutations occur in about 3–4% of lung adenocarcinoma patients and 1–2% of patients with other lung cancer histology. The MET receptor tyrosine kinase and its ligand hepatocyte growth factor (H...

Authors: Leylah M. Drusbosky, Richa Dawar, Estelamari Rodriguez and Chukwuemeka V. Ikpeazu

Targeting Akt in cancer for precision therapy

Biomarkers-guided precision therapeutics has revolutionized the clinical development and administration of molecular-targeted anticancer agents. Tailored precision cancer therapy exhibits better response rate ...

Authors: Hui Hua, Hongying Zhang, Jingzhu Chen, Jiao Wang, Jieya Liu and Yangfu Jiang

Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

The PI3K/AKT/mTOR (PAM) pathway is a key regulator of tumor therapy resistance. We investigated M2698, an oral p70S6K/AKT dual inhibitor, in patients with advanced cancer who failed standard therapies.

Authors: Apostolia-Maria Tsimberidou, Jamie V. Shaw, Dejan Juric, Claire Verschraegen, Amy M. Weise, John Sarantopoulos, Gilberto Lopes, John Nemunaitis, Monica Mita, Haeseong Park, Barbara Ellers-Lenz, Hui Tian, Wenyuan Xiong, Remigiusz Kaleta and Razelle Kurzrock

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

The assessment of measurable residual disease (MRD) in bone marrow has proven of prognostic relevance in patients with multiple myeloma (MM). Nevertheless, and unlike other hematologic malignancies, the use of...

Authors: Joaquin Martinez-Lopez, Rafael Alonso, Sandy W. Wong, Rafael Rios, Nina Shah, Yanira Ruiz-Heredia, Jose Maria Sanchez-Pina, Ricardo Sanchez, Natasha Bahri, Irene Zamanillo, Maria Poza, Natalia Buenache, Cristina Encinas, Luis Juarez, Fatima Miras, Luis Collado…

Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities

B-cell lymphoma is a group of hematological malignancies with high clinical and biological heterogeneity. The pathogenesis of B-cell lymphoma involves a complex interaction between tumor cells and the tumor mi...

Authors: Yingyue Liu, Xiangxiang Zhou and Xin Wang

Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China

The bispecific antibody (bsAbs) research around the world has undergone great changes. We analyzed the global trend of bsAbs research and compared the differences in clinical research of bsAbs between China an...

Authors: Zhonghan Zhang, Fan Luo, Jiaxin Cao, Feiteng Lu, Yang Zhang, Yuxiang Ma, Kangmei Zeng, Li Zhang and Hongyun Zhao

SELP Asp603Asn and severe thrombosis in COVID-19 males

Thromboembolism is a frequent cause of severity and mortality in COVID-19. However, the etiology of this phenomenon is not well understood. A cohort of 1186 subjects, from the GEN-COVID consortium, infected by...

Authors: Chiara Fallerini, Sergio Daga, Elisa Benetti, Nicola Picchiotti, Kristina Zguro, Francesca Catapano, Virginia Baroni, Simone Lanini, Alessandro Bucalossi, Giuseppe Marotta, Francesca Colombo, Margherita Baldassarri, Francesca Fava, Giada Beligni, Laura Di Sarno, Diana Alaverdian…

MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

MYC oncogene is a transcription factor with a wide array of functions affecting cellular activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to the multi-functionality of MYC,...

Authors: Seyed Esmaeil Ahmadi, Samira Rahimi, Bahman Zarandi, Rouzbeh Chegeni and Majid Safa